➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
Boehringer Ingelheim
Dow
Johnson and Johnson
Baxter

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Litigation Details for Nuance Communications Inc. v. Omilia Natural Language Solutions, Ltd. (D. Mass. 2019)


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Nuance Communications Inc. v. Omilia Natural Language Solutions, Ltd. (D. Mass. 2019)

Docket   Start Trial Date Filed 2019-06-28
Court District Court, D. Massachusetts Date Terminated
Cause 35:271 Patent Infringement Assigned To Patti B. Saris
Jury Demand Both Referred To
Parties NUANCE COMMUNICATIONS INC.; OMILIA NATURAL LANGUAGE SOLUTIONS, LTD.
Patents 10,080,733; 10,265,404; 10,508,307; 10,592,168; 8,133,699; 8,227,420; 8,623,834; 8,772,508; 9,090,558; 9,308,276; 9,382,321; 9,404,915; 9,555,112; 9,901,585
Attorneys Carrie Richey; Christian E. Mammen; Christine Dupriest; David Greenbaum; David R. Boaz; Hallie Kiernan; Jennifer Itzkoff; Kevin C. Adam; Kristin Lamb; Raj Gandesha
Firms Nuance Communications, Inc.; White & Case LLP; White & Case, LLP; Womble Bond Dickinson (US) LLP; Womble Bond Dickinson LLP; Womble Bond Dickinson US LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Nuance Communications Inc. v. Omilia Natural Language Solutions, Ltd.
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in Nuance Communications Inc. v. Omilia Natural Language Solutions, Ltd.

Details for Nuance Communications Inc. v. Omilia Natural Language Solutions, Ltd. (D. Mass. 2019)

Date Filed Document No. Description Snippet Link To Document
2020-05-06 92 Memorandum & Order Document 92 Filed 05/06/20 Page 10 of 24 accumulation of patents, no matter how many, is not in and…immunity in enforcing its patent if it obtained that patent through a fraud on the Patent Office, or if its…2014) (quoting Woods v. Wells Fargo Bank, N.A., 733 F.3d 349, 353 (1st Cir. 2013)). In addition…asserting baseless patent infringement litigation using its massive portfolio of acquired patents to drive its…Omilia’s systems infringe three patents owned by Nuance. Two of those patents are at issue in Nuance’s infringement External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Merck
McKinsey
Medtronic
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.